Next Article in Journal
Testing Human Skin and Respiratory Sensitizers—What Is Good Enough?
Next Article in Special Issue
Embryological Results of Couples Undergoing ICSI-ET Treatments with Males Carrying the Single Nucleotide Polymorphism rs175080 of the MLH3 Gene
Previous Article in Journal
Cross-Talk between Cancer Cells and the Tumour Microenvironment: The Role of the 5-Lipoxygenase Pathway
Previous Article in Special Issue
rs657075 (CSF2) Is Associated with the Disease Phenotype (BAS-G) of Ankylosing Spondylitis
Open AccessArticle

Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa–Induced Dyskinesia in Parkinson’s Disease

1
Movement Disorders Centre, Neurology Unit, Department of Translational Medicine, University of Piemonte Orientale, 28100 Novara, Italy
2
Center of Research in Medical Pharmacology, University of Insubria, 21100 Varese, Italy
3
Departments of Biotechnology and Life Science, University of Insubria, 21100 Varese, Italy
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Emil Alexov
Int. J. Mol. Sci. 2017, 18(2), 242; https://doi.org/10.3390/ijms18020242
Received: 31 October 2016 / Revised: 11 January 2017 / Accepted: 16 January 2017 / Published: 24 January 2017
(This article belongs to the Collection Human Single Nucleotide Polymorphisms and Disease Diagnostics)
L-dopa–induced dyskinesia (LID) is a frequent motor complication of Parkinson’s disease (PD), associated with a negative prognosis. Previous studies showed an association between dopamine receptor (DR) gene (DR) variants and LID, the results of which have not been confirmed. The present study is aimed to determine whether genetic differences of DR are associated with LID in a small but well-characterized cohort of PD patients. To this end we enrolled 100 PD subjects, 50 with and 50 without LID, matched for age, gender, disease duration and dopaminergic medication in a case-control study. We conducted polymerase chain reaction for single nucleotide polymorphisms (SNP) in both D1-like (DRD1A48G; DRD1C62T and DRD5T798C) and D2-like DR (DRD2G2137A, DRD2C957T, DRD3G25A, DRD3G712C, DRD4C616G and DRD4nR VNTR 48bp) analyzed genomic DNA. Our results showed that PD patients carrying allele A at DRD3G3127A had an increased risk of LID (OR 4.9; 95% CI 1.7–13.9; p = 0.004). The present findings may provide valuable information for personalizing pharmacological therapy in PD patients. View Full-Text
Keywords: Parkinson’s disease; SNPs; personalized medicine; disease progression; motor complications Parkinson’s disease; SNPs; personalized medicine; disease progression; motor complications
Show Figures

Graphical abstract

MDPI and ACS Style

Comi, C.; Ferrari, M.; Marino, F.; Magistrelli, L.; Cantello, R.; Riboldazzi, G.; Bianchi, M.L.E.; Bono, G.; Cosentino, M. Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa–Induced Dyskinesia in Parkinson’s Disease. Int. J. Mol. Sci. 2017, 18, 242.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map

1
Back to TopTop